Filing Flows › Regen BioPharma (RGBP) › Q3 FY26
Regen BioPharma (RGBP) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 17, 2026
Regen BioPharma (RGBP) reported revenue of $59K for the third quarter fiscal 2026 (Q3 FY26), 0% from a year earlier and 0% from the quarter before. Operating margin was 41.5%.
Regen BioPharma, Q3 FY26: revenue $59K (0% year over year), operating margin 41.5%, net loss $638K, operating cash flow −$24K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | 0% | 0% |
| Operating profit | $25K | — | — |
| Net earnings | −$638K | -164% | — |
| Operating cash flow | −$24K | — | — |
What changed
Revenue was $59K in Q3 FY26, roughly flat year over year and roughly flat from the previous quarter.
Operating profit was $25K, a 41.5% margin (up 110.5 points year over year). Total costs fell 65% while revenue was flat. The quarter ended with a net loss of $638K, after a profit of $1.0M the previous quarter. Net interest and other expense of $662K was the main reason.
Operating cash flow was −$24K. Working capital and other items added $614K.
Questions
What was Regen BioPharma's revenue in the third quarter fiscal 2026?
Regen BioPharma (RGBP) reported revenue of $59K for the third quarter fiscal 2026 (Q3 FY26), 0% from a year earlier and 0% from the quarter before.
Was Regen BioPharma profitable in the third quarter fiscal 2026?
Operating profit was $25K (41.5% of revenue) and net loss $638K.
Source: Regen BioPharma 10-Q on SEC EDGAR.